This site uses cookies. By using this site you agree to receiving cookies. View Policy.

Successfully funded
overfunded
LIFE LENGTH
  • Equity
  • Spain Spain
331%
Raised
£2,154,390
Investors
1085
Target
£650,000
Equity
5.89%
Pre-money valuation
£34,400,000

Life Length is the leading company in the field of telomere diagnostics and analyses worldwide. During the past two years, we have carried out major clinical studies for improved cancer diagnosis and prognosis. Now we plan to launch these services to improve patient care quality.

  • Since 2011 providing telomere testing services in over 35 countries
  • More than 6,000 samples collected in our oncology study
  • Developing a new diagnostic test in prostate cancer
  • Hundreds of thousands of unnecessary biopsies potentially spared

Idea

Over one million unnecessary prostate biopsies are performed yearly in healthy patients due to the lack of accurate screening tests. These biopsies are invasive, expensive and risky, with physical and emotional consequences.

There is an unmet medical need for new biomarkers for prostate cancer screening that can avoid these unnecessary biopsies. Worldwide stats show that about 65% of biopsied patients do not have cancer.

ProsTAV is our sophisticated prostate cancer risk score test that we have developed with our proprietary technology thanks to a clinical study involving 1,200 prostate biopsied patients. Combined with the current screening methodology, this simple blood test can save hundreds of thousands of men each year from unnecessary biopsies, surgeries and needless complications.

Our new test, less expensive and invasive than a biopsy, could save up to 50% of these unnecessary biopsies. It is a huge market with an estimated 6 million cases worldwide. In the UK, it is one of the most frequently diagnosed cancers (over 50,000 annually).

We are the world leader in telomere measurement and we are now combining our Telomere Associated Variables with the current standard of care in cancer. Our technology is the only one commercially available in the world able to extract these variables.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the LIFE LENGTH pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered? Log in

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.